Selank Peptide: Anxiolytic Effects, GABA Modulation, and Clinical Research

What Is Selank?

Selank (TP-7) is a synthetic heptapeptide developed at the Institute of Molecular Genetics of the Russian Academy of Sciences in the 1990s. It was designed by combining the natural tetrapeptide tuftsin (Thr-Lys-Pro-Arg) with a Pro-Gly-Pro sequence that improves metabolic stability and extends its biological half-life [1]. Tuftsin itself is a fragment of the Fc region of immunoglobulin G and plays a well-established role in innate immune function, including phagocyte activation and immune cell modulation.

What makes Selank unusual is that while it was originally developed based on an immune peptide, researchers discovered it possessed significant anxiolytic (anti-anxiety) and nootropic (cognition-enhancing) properties during preclinical testing. This dual action on both the immune system and the central nervous system has made Selank a subject of ongoing interest in neuroimmunology [2].

In Russia, Selank has been approved as a pharmaceutical agent for generalized anxiety disorder and is available as a prescription nasal spray (0.15% solution). It has not received regulatory approval in the United States or European Union, though it remains accessible in some contexts through research chemical suppliers and compounding pharmacies.

Mechanism of Action

GABA System Modulation

The anxiolytic effects of Selank appear to be driven primarily by its interaction with the GABAergic system. Research has demonstrated that Selank enhances the inhibitory effects of GABA in the central nervous system by influencing GABA receptor expression and sensitivity. In a study examining gene expression in hippocampal cells, Selank was shown to alter the expression of 45 genes related to GABAergic neurotransmission, including genes encoding GABA-A receptor subunits [3].

Unlike benzodiazepines, which bind directly to the GABA-A receptor and can produce tolerance, dependence, and cognitive blunting, Selank appears to modulate the GABA system more indirectly. This difference is clinically significant because it means the anxiolytic effect does not come at the cost of sedation or impaired mental clarity [4].

BDNF Upregulation

Brain-derived neurotrophic factor (BDNF) is a protein that supports the survival, growth, and differentiation of neurons. Low BDNF levels have been associated with depression, anxiety disorders, and cognitive decline. Selank has been shown to increase BDNF expression in the hippocampus of experimental animals, with one study demonstrating a significant upregulation of BDNF mRNA within one hour of administration [5].

This BDNF-boosting effect may contribute to both the anxiolytic and nootropic properties of Selank. Higher BDNF levels support synaptic plasticity, which is the brain’s ability to form new connections and adapt to new information. This mechanism is shared with several effective antidepressant treatments, suggesting Selank may operate through pathways that are fundamentally relevant to mood regulation.

Serotonin Metabolism

Selank also influences the serotonergic system, though through a different route than conventional SSRIs. Research has shown that Selank affects the metabolism of serotonin by inhibiting enzymes responsible for serotonin degradation, leading to increased serotonin availability in brain regions associated with emotional regulation [6]. The peptide has been observed to influence the balance of serotonin and its metabolites in the hypothalamus and frontal cortex, areas critically involved in anxiety and mood processing.

Enkephalin Modulation

One of Selank’s less widely discussed mechanisms involves its interaction with the enkephalin system. Enkephalins are endogenous opioid peptides that play a role in pain modulation, stress response, and emotional regulation. Selank has been shown to stabilize enkephalins in blood plasma by inhibiting the enzymes that break them down, effectively extending their activity without introducing exogenous opioids [7]. This mechanism may contribute to the peptide’s calming effects and its apparent ability to improve stress resilience.

Clinical Research

Anxiety Disorders

The most robust clinical data for Selank comes from Russian studies examining its effects on generalized anxiety disorder (GAD). In a randomized clinical trial comparing Selank nasal spray to medazepam (a benzodiazepine), Selank demonstrated comparable anxiolytic efficacy over a 28-day treatment period. Patients receiving Selank showed significant reductions in Hamilton Anxiety Rating Scale scores without the sedation, muscle relaxation, or cognitive impairment associated with the benzodiazepine group [4].

A separate clinical study evaluated Selank in patients with anxiety-phobic disorders and found that the peptide produced noticeable anxiolytic effects within the first week of use. Patients reported reduced rumination, improved emotional stability, and better stress tolerance. Notably, discontinuation did not produce withdrawal symptoms or rebound anxiety, which stands in sharp contrast to benzodiazepine outcomes [8].

Cognitive Enhancement

Selank’s nootropic effects have been documented in both animal and human studies. In human trials, patients treated with Selank showed improvements in attention, memory consolidation, and information processing speed. These cognitive improvements were observed alongside the anxiolytic effects, suggesting that the two benefits are complementary rather than competing [2].

Animal studies have provided more granular data. In rat models, Selank enhanced learning acquisition and memory retention in maze navigation tasks. The cognitive improvements correlated with increased BDNF expression and enhanced synaptic plasticity markers in the hippocampus [5].

Immune Function

Given Selank’s origin as a tuftsin derivative, its immune-modulating properties are not surprising. Research has shown that Selank can influence cytokine profiles, promoting a balanced immune response. In one study, Selank altered the expression of 36 genes involved in inflammatory and immune pathways, including interleukins IL-1, IL-6, and chemokines involved in leukocyte trafficking [9]. The net effect appears to be immunomodulatory rather than simply immunostimulatory, meaning Selank may help normalize immune function rather than push it in a single direction.

Selank vs. Semax: Key Differences

Selank and Semax are often discussed together because both were developed at the same Russian research institute and both are delivered as nasal sprays. However, they have distinct origins, mechanisms, and clinical profiles.

Semax is derived from adrenocorticotropic hormone (ACTH 4-10) with a stabilizing Pro-Gly-Pro tail. Its primary effects are nootropic and neuroprotective, with particular relevance to stroke recovery and cognitive performance under stress. Semax increases BDNF similarly to Selank but acts more prominently on dopaminergic and adrenergic pathways [10].

Selank, by contrast, has a stronger anxiolytic profile and more prominent GABAergic modulation. While both peptides enhance cognition, Selank is generally preferred when anxiety is the primary concern, while Semax is favored for situations requiring enhanced focus, motivation, and mental energy.

Some practitioners recommend combining the two peptides, administering Semax in the morning for cognitive performance and Selank later in the day or during periods of heightened anxiety. This stacking approach takes advantage of their complementary mechanisms, though no formal clinical trials have evaluated the combination.

Nasal Spray Delivery

Selank is predominantly administered as a nasal spray rather than by injection. There are several reasons for this. First, the nasal mucosa provides a relatively direct route to the central nervous system via the olfactory and trigeminal nerve pathways, bypassing the blood-brain barrier to some degree [11]. This is particularly relevant for a peptide whose primary targets are in the brain. Second, nasal delivery avoids first-pass hepatic metabolism, which would degrade much of the peptide before it reached the CNS. Third, it is simply more practical and patient-friendly than daily injections.

The standard pharmaceutical preparation in Russia is a 0.15% solution, meaning each drop contains approximately 75 mcg of Selank. The typical dosing protocol involves 2 to 3 drops per nostril, administered 2 to 3 times per day, yielding a total daily dose of approximately 600 to 900 mcg [1].

Proper technique matters for nasal spray peptide delivery. Patients are generally advised to clear the nasal passages before administration, tilt the head slightly forward (not back), and avoid blowing the nose for several minutes after dosing to allow adequate mucosal absorption.

Dosing Protocols

Because Selank has not been evaluated in FDA-regulated clinical trials, dosing recommendations are drawn from Russian clinical research and practitioner experience.

Standard Protocol

• Dose: 250 to 750 mcg per day, divided into 2 to 3 administrations
• Route: Intranasal spray
• Duration: 14 to 28 days per cycle
• Onset: Anxiolytic effects often noticeable within 5 to 15 minutes; full cognitive benefits may take 1 to 2 weeks of consistent use

Cycling Considerations

Russian clinical guidelines generally recommend treatment courses of 14 days, with the option to extend to 28 days for more pronounced or chronic anxiety. Some practitioners cycle Selank with rest periods of 1 to 2 weeks between courses, though the absence of tolerance development in clinical studies suggests that continuous use may also be reasonable [8].

Subcutaneous Injection

Although nasal delivery is the standard route, some practitioners do prescribe Selank via subcutaneous injection, particularly when compounding pharmacy nasal preparations are unavailable. Injectable doses are typically lower (150 to 500 mcg per day) due to higher systemic bioavailability compared to nasal administration. However, this route may be less effective for CNS-targeted effects because it does not benefit from the direct nose-to-brain transport pathway.

Side Effects and Safety Profile

Selank has demonstrated a favorable safety profile across clinical studies. The most commonly reported side effects are mild and localized:

• Mild nasal irritation or a brief burning sensation after intranasal administration
• Occasional mild fatigue during the first few days of use
• Rare reports of headache

No serious adverse events have been reported in published clinical studies. Critically, Selank has not shown the sedation, cognitive impairment, motor incoordination, dependence potential, or withdrawal effects associated with benzodiazepines [4]. Toxicology studies in animals have confirmed a very wide therapeutic index, with no lethal dose identified at multiples far exceeding clinical doses [12].

That said, the total body of safety data is smaller than what would be required for FDA approval, and long-term safety data beyond 28-day treatment courses is limited. Individuals with autoimmune conditions should exercise caution given Selank’s immunomodulatory properties, and pregnant or breastfeeding women should avoid the peptide due to a lack of reproductive safety data.

Legal Status and Availability

Selank occupies a gray area in many Western countries. In Russia, it is an approved pharmaceutical with the trade name Selank and is available by prescription. In the United States, Selank is not FDA-approved, not scheduled as a controlled substance, and falls into the general category of research peptides. It can be obtained through some compounding pharmacies with a physician’s prescription, or purchased from research chemical suppliers as a “research chemical not for human consumption” [13].

The regulatory landscape for peptides in the U.S. has been shifting. The FDA’s evolving stance on compounded peptides has introduced new uncertainty about the long-term availability of many peptides through compounding channels. Anyone considering Selank should work with a licensed healthcare provider who can prescribe through legitimate compounding pharmacies that adhere to USP standards for sterility and potency testing.

Related Reading

• Peptide Therapy: Complete Guide
• Peptide Injections: Types, Technique, and What to Know
• Are Peptides Safe? Understanding Risks and Benefits
• Thymosin Alpha-1: Immune Modulation and Clinical Research

References

1. Zozulya AA, Sokolov OY, Seredenin SB, et al. “The inhibitory effect of Selank on enkephalin-degrading enzymes as a possible mechanism of its anxiolytic activity.” Bull Exp Biol Med. 2001;131(4):315-317. doi:10.1023/A:1017979514274
2. Meshavkin VK, Kost NV, Sokolov OY, et al. “Selank (TKPRPGP) modulation of the expression of genes encoding the neurotensin receptors in rat brain.” Mol Genet Microbiol Virol. 2014;29(4):230-234. doi:10.3103/S0891416814040077
3. Volkova A, Sharova E, Kushnirov G, et al. “Selank modulates the expression of genes encoding GABAergic system components in the hippocampus of rats.” Dokl Biochem Biophys. 2016;468(1):216-218. doi:10.1134/S1607672916030157
4. Medvedev VE, Tereshchenko ON, Kost NV, et al. “Comparison of the anxiolytic effect of Selank and medazepam in patients with generalized anxiety disorder.” Zh Nevrol Psikhiatr Im S S Korsakova. 2014;114(7):17-22. PMID: 25176260
5. Inozemtseva LS, Karpenko EA, Dolotov OV, et al. “Intranasal administration of the peptide Selank regulates BDNF expression in the rat hippocampus in vivo.” Dokl Biol Sci. 2008;421(1):241-243. doi:10.1134/S0012496608040066
6. Semenova TP, Kozlovskaya MM, Zuikov AV, et al. “Effect of Selank on serotonin metabolism in the brain of rats.” Eksp Klin Farmakol. 2009;72(4):6-8. PMID: 19803361
7. Kozlovskaya MM, Kozlovskii II, Val’dman EA, Seredenin SB. “Selank and short peptides of the tuftsin family in the regulation of adaptive behavior in stress.” Neurosci Behav Physiol. 2003;33(9):853-860. doi:10.1023/A:1025988519919
8. Zozulya AA, Kost NV, Sokolov OY, et al. “Selank: an anxiolytic peptide with nootropic and immunomodulatory properties.” Biol Bull. 2008;35(6):551-557. doi:10.1134/S1062359008060010
9. Andreeva LA, Mezentseva MV, Nagaev IB, et al. “Selank effects on gene expression of cytokines and chemokines.” Russ J Genet. 2010;46(10):1205-1209. doi:10.1134/S1022795410100108
10. Dolotov OV, Karpenko EA, Inozemtseva LS, et al. “Semax, an analog of ACTH(4-10) with cognitive effects, regulates BDNF and trkB expression in the rat hippocampus.” Brain Res. 2006;1117(1):54-60. doi:10.1016/j.brainres.2006.07.108
11. Dhuria SV, Hanson LR, Frey WH 2nd. “Intranasal delivery to the central nervous system: mechanisms and experimental considerations.” J Pharm Sci. 2010;99(4):1654-1673. doi:10.1002/jps.21924
12. Seredenin SB, Kozlovskaya MM, Blednov YA, et al. “The anxiolytic action of an analog of an endogenous peptide tuftsin on behavior of mice in the elevated plus-maze.” Zh Vyssh Nerv Deiat Im I P Pavlova. 1998;48(1):153-160. PMID: 9585207
13. US Food and Drug Administration. “Compounding and the FDA: Questions and Answers.” FDA Guidance Document. 2023.